Dupixent’s march continues with Japanese COPD nod

Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.

Following recent regulatory authorizations in the European Union, China, and the USA, this approval of the Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN) drug was based on pivotal Phase III results in adults with elevated eosinophils.

In the study, Dupixent significantly reduced exacerbations and improved lung function compared to placebo.